Oral Peptide Delivery Challenges

The gut is not a welcoming place for peptides

About 95% of peptide-based therapeutics currently in development or clinical use require injection. That number has barely budged in decades, and honestly, if you've spent any time looking at the pharmacokinetics literature, it's not hard to see why. Oral peptide delivery, the route every patient would prefer, throws up a series of barriers that are almost elegant in how completely they dismantle a peptide before it reaches systemic circulation.

Understanding those barriers isn't just academic. It shapes which molecules ever make it to patients, what routes of administration get approved, and why the regulatory pathway for an oral peptide product looks so much harder than for a small molecule. If you want the wider picture first, our pieces on why most peptides are injectable and routes of administration compared set the scene.

Barrier one: the proteolytic gauntlet

Swallow a peptide and you're immediately in trouble. The stomach's acidic environment (pH 1.5–3.5 under fasting conditions) begins denaturing the molecule before it even reaches the small intestine. Then comes the main event: proteolytic enzymes. Pepsin in the stomach, then trypsin, chymotrypsin, elastase, and a cascade of brush-border peptidases in the small intestine, all of them evolved specifically to break peptide bonds and liberate free amino acids for absorption.

That's the digestive system doing its job perfectly. For a drug developer, it's a nightmare.

A linear peptide with unmodified termini typically has a half-life measured in minutes in simulated intestinal fluid. Some are gone in seconds. Even cyclic peptides, which are inherently more resistant due to their constrained conformation, don't escape entirely; they're just slower to degrade. For background on why that stability figure matters, see our explainer on peptide half-life.

Barrier two: permeation across the intestinal epithelium

Let's say your peptide somehow survives the luminal enzymes. It still has to cross the intestinal epithelium, a tightly regulated selective barrier. Most small molecules cross passively through lipid membranes. Peptides, being hydrophilic and often carrying charge, can't do that efficiently. And the larger the peptide, the worse the permeation; there's a rough inverse relationship between molecular weight and passive permeability that becomes punishing above about 500 Da.

The tight junctions between enterocytes, the cells lining the gut, are another obstacle. Paracellular transport (slipping between cells) is possible for very small molecules but essentially closed to anything peptide-sized. Transcellular routes exist: endocytosis, receptor-mediated transport, and in some cases transporter-mediated uptake. But these are highly substrate-specific. Most peptides don't have a convenient transporter waiting for them.

There's also efflux to consider. P-glycoprotein and related ABC transporters actively pump substrates back into the intestinal lumen. Some peptides are substrates; this can reduce net absorption substantially, though the extent varies considerably by structure.

Barrier three: first-pass metabolism

Anything that does make it across the epithelium enters the portal circulation and heads straight to the liver, the organ that, evolutionarily speaking, exists partly to catch things the gut wall missed. Peptidases in the portal blood and liver can continue degradation. This hepatic first-pass effect, combined with the luminal and epithelial barriers, is why bioavailability for oral peptides is so brutally low. For many unmodified peptides it's below 1–2%.

I find this genuinely fascinating, by the way. The same mechanisms that make the oral route so hostile to exogenous peptides are a large part of why the gut works as a signalling organ at all. The rapid degradation of gut-derived peptides like GLP-1 (half-life under 2 minutes in plasma) is a feature, not a bug, it allows tight, local regulation. It just happens to make the GLP-1 receptor agonist pharmacology story very complicated from a delivery standpoint.

The first-pass metabolism article in our glossary goes into the mechanics in more detail if you want the broader picture; it's relevant across a lot of molecule classes, not just peptides. Our overview of peptide pharmacokinetics covers how absorption fits with the rest of a molecule's journey through the body.

What researchers are doing about oral peptide delivery

The short version is: a lot, and most of it is still early-stage. The main strategies are instructive about where the field is heading.

Chemical modification

N-methylation of backbone amides, D-amino acid substitution, PEGylation, lipidation, these all aim to reduce protease recognition or improve membrane permeability. The GLP-1-based oral formulation that reached late-stage development (you'd know the molecule category; I won't name brands here) relies on a combination of structural modification to resist DPP-4 cleavage and a specific absorption enhancer to get across the epithelium. That approach took years of iterative chemistry to get right. We cover the half-life side of this in PEGylation and half-life extension.

D-amino acid substitution is particularly interesting from a pharmacokinetics standpoint. Proteases are largely stereospecific, they've evolved to cleave L-amino acid sequences. Swap even one key residue to the D-configuration and you can dramatically extend luminal half-life. The trade-off is that receptor binding is often disrupted, so you can't just invert everything. It's a balancing act.

Permeation enhancers

These are co-formulated excipients that transiently increase epithelial permeability, either by disrupting tight junctions or by modifying membrane fluidity. Fatty acid derivatives, bile salts, and chelating agents like EDTA have all been investigated. They work, in the sense that they increase permeation, but reproducibility in humans is difficult. Fed versus fasted state, gut motility, bile output, luminal pH, all of these vary between individuals and between dosing occasions and affect how well an enhancer performs.

In my view, permeation enhancers are probably underrated as a near-term strategy because they don't require redesigning the peptide itself, but the variability problem is real and the safety profile of chronic tight-junction disruption warrants careful study.

Nanoparticle and encapsulation systems

Polymeric nanoparticles, liposomes, self-emulsifying systems, and mucoadhesive microparticles can protect peptides from enzymatic degradation and assist with mucosal transport. Some systems exploit transcytosis pathways, particularly the neonatal Fc receptor (FcRn), which is expressed in adult gut epithelium and normally handles IgG recycling. Fc-fusion peptides can hitch a ride on this pathway. It's elegant science. Our article on liposomal delivery systems explains the carrier concept in more general terms.

The challenge is manufacturing. Reproducible nanoparticle production at commercial scale, with consistent size distribution and encapsulation efficiency, is genuinely hard. The TGA's Good Manufacturing Practice requirements don't get easier when your dosage form is a nanoparticle suspension with a 200-nm target particle size.

Site-specific delivery

Colon-targeted formulations can reduce exposure to upper-GI proteases and take advantage of lower enzymatic activity and a larger mucosal surface area. Some enteric-coated systems aim for specific small-intestine windows where transporter expression is higher. The colon also has a microbiome that can either help or hinder, depending on the molecule, certain peptide structures are substrates for bacterial peptidases too.

The interplay between gut microbiota composition and peptide bioavailability is a legitimately open research question.

The regulatory picture in Australia

Any oral peptide formulation seeking a place on the Australian Register of Therapeutic Goods (ARTG) needs to demonstrate bioequivalence or efficacy through clinical data, and the chemistry, manufacturing and controls (CMC) package for a novel delivery system is substantial. Peptides that have been reformulated for oral delivery often require new clinical trials rather than bridging from existing injection-route data, because the pharmacokinetic profile can differ enough to make assumptions about equivalence unreliable. Our piece on how clinical trials move from lab to patient explains why that evidence matters.

It's also worth flagging that the peptide products circulating online, marketed for performance or body composition, are frequently unapproved, and supplying them without TGA approval is illegal in Australia. The TGA has been actively enforcing this, including through the Schedule 4 framework. These products are categorically different from the research-stage oral delivery systems I've been describing above. Schedule 4 (prescription only) classification means a valid prescription and a registered product, full stop.

If a peptide isn't on the ARTG and isn't accessed via the Special Access Scheme or an Authorised Prescriber pathway, it has no legal pathway to a patient in Australia. That's not a technicality; it's the framework.

Where the field actually is

A handful of oral peptide formulations have made it to market globally, primarily in the insulin and GLP-1 space, but these represent the exception. They've required enormous investment in formulation science and long development timelines. For most peptide classes, subcutaneous injection remains the only viable route that delivers predictable systemic exposure.

That's not a failure of the science, exactly. It's more that the problem is hard in ways that compound on each other: chemical instability, physical barriers, variable physiology, and manufacturing complexity all have to be solved simultaneously for the same molecule. Progress is real, though. The 2020 approval of oral semaglutide in multiple jurisdictions was a genuine milestone, not because the bioavailability is high (it isn't, it's around 1%) but because the clinical data were sufficient despite that.

The next decade will be interesting to watch, particularly as structure-activity relationships around peptide permeability become better understood and computational tools for predicting gut stability mature. Whether that translates into a broader wave of oral peptides reaching Australian patients is still an open question.

Sources

• Oral Peptide Delivery: Challenges and Strategies; National Center for Biotechnology Information (NCBI/NIH)
• Australian Regulatory Guidelines for Prescription Medicines, Therapeutic Goods Administration (TGA)
• Strategies for Improving Oral Bioavailability of Peptides and Proteins, NCBI/NIH
• WHO Expert Committee on Biological Standardization; WHO

Priya Nandakumar, Pharmacology writer, peptides & PK